Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | APLNR | P35414 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | CTSD | P07339 | 1/20 | 0.30 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29746689 | 0.86 | CA14 (0.40) | CA14SSTR4HDAC6APLNRHDAC1 | |
| SCHEMBL24323748 | 0.84 | SSTR4 (0.42) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL3667144 | 0.84 | SSTR4 (0.42) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL503444 | 0.83 | CA14 (0.53) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL13163338 | 0.83 | SSTR4 (0.41) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL12723119 | 0.83 | SSTR4 (0.41) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL1761184 | 0.81 | SSTR4 (0.40) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL28584989 | 0.81 | CA14 (0.51) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL745378 | 0.81 | CA14 (0.51) | CA14SSTR4HDAC6HDAC1HDAC2 | |
| SCHEMBL4472315 | 0.80 | SSTR4 (0.40) | CA14SSTR4HDAC6HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119176820-A | Tricyclic compounds as MAT2A inhibitors | 艾立康药业股份有限公司 | 2024-12-24 | — | — | CN | disclosed |